SCHEMBL1693302

SCHEMBL1693302

CC(=O)n1ncc2c(F)c(Br)ccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 2/20 0.44
AURKA O14965 2/20 0.44
DAPK3 O43293 2/20 0.44
GSK3A P49840 2/20 0.44
LIMK1 P53667 2/20 0.44
CSNK1A1 P48729 1/20 0.44
IKBKE Q14164 1/20 0.44
MAPK14 Q16539 1/20 0.44
TAOK1 Q7L7X3 1/20 0.44
CLK4 Q9HAZ1 1/20 0.44
DYRK1B Q9Y463 1/20 0.44
CREBBP Q92793 1/20 0.40
NPC1 O15118 7/20 0.39
RAB9A P51151 7/20 0.39
KMT2A Q03164 4/20 0.38
CDK5 Q00535 2/20 0.36
PDGFRA P16234 1/20 0.36
TYRO3 Q06418 1/20 0.36
SLC2A1 P11166 2/20 0.34
MEN1 O00255 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24427867 0.80 ELANE (0.39) TAOK1CLK4NPC1RAB9AKMT2A
SCHEMBL16228613 0.79 CHEK1 (0.42) CHEK1AURKADAPK3GSK3ALIMK1
SCHEMBL15265938 0.78 CHEK1 (0.41) CHEK1AURKADAPK3GSK3ALIMK1
SCHEMBL5410344 0.78 CHEK1 (0.41) CHEK1AURKADAPK3GSK3ALIMK1
SCHEMBL190246 0.78 NPC1 (0.52) CHEK1AURKADAPK3GSK3ALIMK1
SCHEMBL14995449 0.77 CHEK1 (0.39) CHEK1AURKADAPK3GSK3ALIMK1
SCHEMBL4120013 0.77 CHEK1 (0.40) CHEK1AURKADAPK3GSK3ALIMK1
SCHEMBL4526748 0.75 HTT (0.34) KMT2AMEN1HTTSMN1; SMN2CDK2
SCHEMBL16227960 0.74 CHEK1 (0.36) CHEK1AURKADAPK3GSK3ALIMK1
SCHEMBL25366934 0.73 CHEK1 (0.42) CHEK1AURKADAPK3GSK3ALIMK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4638421-A1 PROCESS TO MAKE GLP1 RA AND INTERMEDIATES THEREFOR Eli Lilly and Company (US) 2025-10-29 EP disclosed
US-12365682-B2 Process to make GLP1 RA and intermediates therefor ELI LILLY AND COMPANY (US) 2025-07-22 US disclosed
US-20250042899-A1 PROCESS TO MAKE GLP1 RA AND INTERMEDIATES THEREFOR CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-02-06 US disclosed
WO-2024137426-A1 PROCESS TO MAKE GLP1 RA AND INTERMEDIATES THEREFOR ELI LILLY AND COMPANY (US) 2024-06-27 WO disclosed
US-8796256-B2 Substituted thiazolidinedione indazoles, indoles and benzotriazoles as estrogen-related receptor-α modulators JANSSEN PHARMACEUTICA NV (BE) 2014-08-05 US disclosed
WO-2011149841-A1 SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-α MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2011-12-01 WO disclosed
US-20110294780-A1 SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2011-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12365682-B2 Process to make GLP1 RA and intermediates therefor GLP1R, GIPR, NPY4R CHEK1 4851/4885AURKA 4042/4885DAPK3 900/4885
US-20110294780-A1 SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS ESR2, IGF1R, ESRRA CHEK1 2272/4885AURKA 4365/4885DAPK3 3235/4885
US-20250042899-A1 PROCESS TO MAKE GLP1 RA AND INTERMEDIATES THEREFOR GLP1R, GIPR, NPY4R CHEK1 4851/4885AURKA 4042/4885DAPK3 900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.